Related Experiment Video
Updated: Aug 6, 2026
08:15
Gastrointestinal Motility Monitor (GIMM)
Published on: December 1, 2010
[The gastrointestinal motor function in irritable bowel syndrome (IBS)]
Yasuhiro Sagami1, Michio Hongo
1Department of Psychosomatic Medicine, Tohoku University Hospital.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|August 11, 2006
Summary
Corticotropin-releasing hormone (CRH) significantly impacts irritable bowel syndrome (IBS) by affecting gut motility and symptoms. Blocking CRH may offer a therapeutic approach for IBS patients experiencing exaggerated stress responses.
Area of Science:
- Neurogastroenterology
- Gastrointestinal Motility Disorders
- Brain-Gut Interaction
Context:
- Irritable bowel syndrome (IBS) is characterized by altered brain-gut interactions.
- Psychological stress and colonic stimuli exacerbate colonic motor function, particularly in IBS patients.
- The brain-gut axis plays a crucial role in IBS pathophysiology.
Purpose:
- To investigate the role of Corticotropin-releasing hormone (CRH) in the brain-gut interaction of IBS.
- To determine if CRH mediates exaggerated colonic responses in IBS.
- To evaluate the therapeutic potential of CRH antagonists in IBS.
Summary:
- Corticotropin-releasing hormone (CRH) is identified as a key mediator in the brain-gut interaction relevant to IBS.
- Peripheral CRH administration amplifies colonic motility, induces abdominal symptoms, and stimulates ACTH secretion, with these effects being more pronounced in IBS patients.
- CRH antagonists effectively mitigate the heightened colonic motor responses observed in IBS patients.
Impact:
- CRH is implicated as a central peptide in the pathophysiology of IBS.
- Understanding CRH's role offers potential new therapeutic targets for IBS management.
- This research highlights the significance of stress pathways in gastrointestinal disorders.
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:23Irritable Bowel Syndrome
DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
01:20Gastrointestinal Motility Disorders
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...